Published in Women's Health Weekly, October 18th, 2007
"Clarification of a regulatory pathway from the FDA for testosterone ATD(TM) gel is very important news that reopens the prospects for approval in the U.S. as well as in Europe, each large potential markets, after several years of little regulatory progress. It also demonstrates the approvability of our core gel platform while emphasizing the flexibility of our technology in the key therapeutic area of women's health," commented Jack E....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.